RetnaGene AMD

Determining the value in genetic testing for AMDFor any treatment to be successful, early detection is key. For that reason, genetic testing may play a role in determining the frequency of follow-up in patients who are determined to have high-risk alleles.
Current views on genetic testing for AMDGenetic testing in AMD is a relatively new focus for optometrists and an important one to ensure that we are getting a complete view of our patients’ risk for developing advanced AMD. Although we are making some progress, we still have work to do to gain a better understanding of how to incorporate its use into clinical practice.
Nicox launches expanded access to Sequenom’s RetnaGene tests in U.S.Nicox Inc. is launching expanded access to Sequenom Laboratories’ RetnaGene portfolio of genetic tests—RentaGene AMD and RetnaGene LR—which asses an individual’s risk for advanced age-related macular degeneration (AMD).
AMD genetic testing could lead to early diagnosis, better treatmentOptometry Times Editorial Advisory Board members Steven Ferrucci, OD, FAAO, and Diana Shechtman, OD, FAAO, discussed the benefits of genetic tests for age-related macular degeneration (AMD) at the American Optometric Association’s Optometry’s Meeting.
Nicox, Sequenom enter marketing agreement for new AMD testNicox Inc. has been granted the North American promotional rights to Sequenom Laboratories’ RetnaGene AMD laboratory-developed test for the evaluation of a patient’s risk of age-related macular degeneration (AMD) disease progression within 2, 5, and 10 years.